Sprache: Englisch
Verlag: LAP LAMBERT Academic Publishing, 2012
ISBN 10: 3659228176 ISBN 13: 9783659228179
Anbieter: Books Puddle, New York, NY, USA
Zustand: New.
Sprache: Englisch
Verlag: Lap Lambert Academic Publishing, 2012
ISBN 10: 3659228176 ISBN 13: 9783659228179
Anbieter: Revaluation Books, Exeter, Vereinigtes Königreich
EUR 99,24
Anzahl: 1 verfügbar
In den WarenkorbPaperback. Zustand: Brand New. 84 pages. 8.66x5.91x0.19 inches. In Stock.
Sprache: Englisch
Verlag: LAP LAMBERT Academic Publishing, 2013
ISBN 10: 3659228176 ISBN 13: 9783659228179
Anbieter: preigu, Osnabrück, Deutschland
Taschenbuch. Zustand: Neu. Identification Of Possible Biomarkers In Non-Small Cell Lung Cancer | Identification Of Possible New Biomarkers In Non-small Cell Lung Cancer Using Microarray Analysis Of Raw Patient Data | Pramod Gware (u. a.) | Taschenbuch | 84 S. | Englisch | 2013 | LAP LAMBERT Academic Publishing | EAN 9783659228179 | Verantwortliche Person für die EU: preigu GmbH & Co. KG, Lengericher Landstr. 19, 49078 Osnabrück, mail[at]preigu[dot]de | Anbieter: preigu.
Sprache: Englisch
Verlag: LAP LAMBERT Academic Publishing Sep 2012, 2012
ISBN 10: 3659228176 ISBN 13: 9783659228179
Anbieter: BuchWeltWeit Ludwig Meier e.K., Bergisch Gladbach, Deutschland
Taschenbuch. Zustand: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -Research is a high concept; it brings to test our patience, vigor and dedication. Every result arrived at a beginning for higher achievements. Our project in the same interest is just a drop in the ocean. At the same time Cancer biomarker based diagnostics have applications for establishing disease predisposition, early detection, cancer staging, therapy selection, identifying whether or not a cancer is metastatic, therapy monitoring, assessing prognosis, and advances in the adjuvant setting. New laboratory methods, improvements in the tools available to scientists, and an overriding need to improve cancer therapies are driving current efforts to map cancer-related changes in the body. These changes encompass predisposition or risk factors associated with cancer and subsequent developments of the disease. The need to identify and understand cancer biomarkers is being driven by a number of factors. These include requirements to improve screening and early detection, to provide better guidance on therapy, and to avoid therapy resistance attributes, for understanding cancer staging, response to treatment, and prognosis. 84 pp. Englisch.
Sprache: Englisch
Verlag: LAP LAMBERT Academic Publishing, 2012
ISBN 10: 3659228176 ISBN 13: 9783659228179
Anbieter: Majestic Books, Hounslow, Vereinigtes Königreich
EUR 77,00
Anzahl: 4 verfügbar
In den WarenkorbZustand: New. Print on Demand.
Sprache: Englisch
Verlag: LAP LAMBERT Academic Publishing, 2012
ISBN 10: 3659228176 ISBN 13: 9783659228179
Anbieter: Biblios, Frankfurt am main, HESSE, Deutschland
Zustand: New. PRINT ON DEMAND.
Sprache: Englisch
Verlag: LAP LAMBERT Academic Publishing, 2012
ISBN 10: 3659228176 ISBN 13: 9783659228179
Anbieter: moluna, Greven, Deutschland
EUR 41,05
Anzahl: Mehr als 20 verfügbar
In den WarenkorbZustand: New. Dieser Artikel ist ein Print on Demand Artikel und wird nach Ihrer Bestellung fuer Sie gedruckt. Autor/Autorin: Gware PramodMyself Pramod Gware working as an Assistant Professor in Department of Biotechnology Anand Engineering College, Agra from past 3.5 years. I did my graduation and post graduation in Biotechnology Engineering. I had few pub.
Sprache: Englisch
Verlag: LAP LAMBERT Academic Publishing Sep 2012, 2012
ISBN 10: 3659228176 ISBN 13: 9783659228179
Anbieter: buchversandmimpf2000, Emtmannsberg, BAYE, Deutschland
Taschenbuch. Zustand: Neu. This item is printed on demand - Print on Demand Titel. Neuware -Research is a high concept; it brings to test our patience, vigor and dedication. Every result arrived at a beginning for higher achievements. Our project in the same interest is just a drop in the ocean. At the same time Cancer biomarker¿based diagnostics have applications for establishing disease predisposition, early detection, cancer staging, therapy selection, identifying whether or not a cancer is metastatic, therapy monitoring, assessing prognosis, and advances in the adjuvant setting. New laboratory methods, improvements in the tools available to scientists, and an overriding need to improve cancer therapies are driving current efforts to map cancer-related changes in the body. These changes encompass predisposition or risk factors associated with cancer and subsequent developments of the disease. The need to identify and understand cancer biomarkers is being driven by a number of factors. These include requirements to improve screening and early detection, to provide better guidance on therapy, and to avoid therapy resistance attributes, for understanding cancer staging, response to treatment, and prognosis.VDM Verlag, Dudweiler Landstraße 99, 66123 Saarbrücken 84 pp. Englisch.
Sprache: Englisch
Verlag: LAP LAMBERT Academic Publishing, 2012
ISBN 10: 3659228176 ISBN 13: 9783659228179
Anbieter: AHA-BUCH GmbH, Einbeck, Deutschland
Taschenbuch. Zustand: Neu. nach der Bestellung gedruckt Neuware - Printed after ordering - Research is a high concept; it brings to test our patience, vigor and dedication. Every result arrived at a beginning for higher achievements. Our project in the same interest is just a drop in the ocean. At the same time Cancer biomarker based diagnostics have applications for establishing disease predisposition, early detection, cancer staging, therapy selection, identifying whether or not a cancer is metastatic, therapy monitoring, assessing prognosis, and advances in the adjuvant setting. New laboratory methods, improvements in the tools available to scientists, and an overriding need to improve cancer therapies are driving current efforts to map cancer-related changes in the body. These changes encompass predisposition or risk factors associated with cancer and subsequent developments of the disease. The need to identify and understand cancer biomarkers is being driven by a number of factors. These include requirements to improve screening and early detection, to provide better guidance on therapy, and to avoid therapy resistance attributes, for understanding cancer staging, response to treatment, and prognosis.